ARS Pharmaceuticals(SPRY)2025-03-20 11:02Financial Performance - Preliminary nef y® net product revenue for Q4 2024 was approximately 7.1 million since launch[5]. - Cash, cash equivalents, and short-term investments were approximately $314.0 million as of December 31, 2024, expected to support operations for at least three years[5]. - The company aims to achieve a long-term total gross-to-net revenue target of 50% through consistent contracting[9]. Product Delivery and Usage - Over 14,500 nef y two-pack units were delivered in Q4 2024, including more than 1,500 units in the last week of the year[5]. - More than 3,000 healthcare providers have prescribed nef y to date, with 80% in the highest decile for prescribing epinephrine[5]. - More than 1,750 healthcare providers have participated in the nef y Experience Program to date[5]. Market Strategy and Coverage - The company is on track for over 60% commercial insurance coverage by the end of Q1 2025 and over 80% by the end of Q3 2025[9]. - A branded direct-to-consumer marketing campaign for nef y is set to launch in May 2025, aimed at increasing brand recognition[9]. Regulatory and Conference Participation - The sNDA for nef y 1 mg for children weighing 15 to 30 kg has a PDUFA target action date of March 6, 2025, with expected product availability in Q2 2025[9]. - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025[1].